1,749,142 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Bought by Toronto Dominion Bank

Toronto Dominion Bank acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,749,142 shares of the company's stock, valued at approximately $18,628,000. Toronto Dominion Bank owned 7.46% of UroGen Pharma at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new position in UroGen Pharma during the fourth quarter worth $59,000. Lazard Asset Management LLC acquired a new stake in UroGen Pharma during the 4th quarter worth about $67,000. Aquatic Capital Management LLC bought a new position in shares of UroGen Pharma in the 4th quarter worth about $101,000. Oppenheimer & Co. Inc. bought a new position in shares of UroGen Pharma in the 4th quarter worth about $126,000. Finally, ProShare Advisors LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at about $137,000. 91.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price for the company. Scotiabank started coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price objective for the company. Guggenheim reissued a "buy" rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of UroGen Pharma in a research note on Tuesday, May 13th. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Trading Up 9.0%

NASDAQ:URGN opened at $7.97 on Tuesday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a one year low of $6.46 and a one year high of $20.70. The company has a market cap of $367.47 million, a PE ratio of -2.53 and a beta of 0.66. The firm has a 50-day moving average of $10.53 and a 200-day moving average of $10.85.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analysts' expectations of $22.71 million. As a group, equities research analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UroGen Pharma Ltd. (NASDAQ:URGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.